First-Line Pembrolizumab Improves Survival in Triple-Negative Breast Cancer

Following publication of an interim analysis in 2020, the data from the phase 3 KEYNOTE-522 study (N Engl J Med ...

NOVEMBER 25, 2024

Social Determinants of Health Affect Genetic Screening Rates in TNBC

A report from the US Oncology Network/Ontada revealed that overall, only 75% of patients with triple-negative ...

JULY 21, 2023

Neoadjuvant Pembrolizumab Modifies Tumor Burden Effect in Triple-Negative Breast Cancer

Neoadjuvant pembrolizumab (Keytruda, Merck) was licensed for use in patients with previously untreated ...

JULY 11, 2022

Sacituzumab Shines in ASCENT TNBC Trial

The novel antibody–drug conjugate sacituzumab govitecan-hziy has provided an overall survival benefit over ...

APRIL 5, 2021

Olaparib Provides PFS Benefit in Pts With HER2-Negative Breast Cancer

Chicago—Relative to single-agent chemotherapies, olaparib delays time to both first and second progression in ...

JULY 12, 2017

Beta Blockers May Improve PFS in Breast Cancer Patients

Beta blockers may increase progression-free survival (PFS) in HER2-negative and triple-negative breast cancer ...

JUNE 13, 2017

Researchers Debate Role of
Pre-op Carboplatin in TNBC

San Antonio—Should clinicians routinely use carboplatin in the neoadjuvant setting for triple-negative breast ...

FEBRUARY 29, 2016